Current trends in perioperative treatment of resectable gastric cancer

doi:10.4240/wjgs.v15.i3.323

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3971)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

299

WORD

HTML

2713

Figures (1-1)

230

Tables (1-2)

270

Sum=3552

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

126

Download

293

Sum=419

Mar 27, 2023 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastrointest Surg. Mar 27, 2023; 15(3): 323-337
Published online Mar 27, 2023. doi: 10.4240/wjgs.v15.i3.323

Table 2 Overview of ongoing trials of biological and immunological agents in the perioperative treatment for gastric cancer

NCT	Agent	Target structure	Trial	Phase	Study design	Primary endpoint	Ref.
NCT04592913	Durvalumab	PD-L1	Matterhorn	III	FLOT + durvalumab	EFS	[72]
NCT04592913	Durvalumab	PD-L1	Matterhorn	III	FLOT + placebo	EFS	[72]
NCT03221426	Pembrolizumab	PD-1	Keynote-585	III	CF/FLOT + pembrolizumab	pCR, OS, EFS	[73]
NCT03221426	Pembrolizumab	PD-1	Keynote-585	III	FLOT + placebo	pCR, OS, EFS	[73]
NCT03421288	Atezolizumab	PD-L1	Dante	II	FLOT + atezolizumab	DFS	[50]
NCT03421288	Atezolizumab	PD-L1	Dante	II	FLOT + placebo	DFS	[50]
NCT03399071	Avelumab	PD-L1	Iconic	II	FLOT + avelumab	pCR	[74]
NCT05504720	Pembrolizumab + trastuzumab	PD-1/HER2	PherFlot	II	FLOT + pembrolizumab + trastuzumab	DFS, pCR	[75]
NCT02205047	Trastuzumab +/- pertuzumab	HER2	Innovation	II	CT	pCR	[76]
					CT + trastuzumab
					CT + trastuzumab + pertzumab

CF: Cisplatin and 5-fluorouracil; CT: Chemotherapy; DFS: Disease free survival, EFS: Event free survival; FLOT: Fluorouracil, leucovorin, oxaliplatin, docetaxel; HER: Human epidermal growth factor; OS: Overall survival; pCR: Pathological complete response; PD: Programmed cell death; PDL: Programmed cell death ligand.

Citation: Yıldız İ, Özer L, Şenocak Taşçı E, Bayoglu İV, Aytac E. Current trends in perioperative treatment of resectable gastric cancer. World J Gastrointest Surg 2023; 15(3): 323-337
URL: https://www.wjgnet.com/1948-9366/full/v15/i3/323.htm
DOI: https://dx.doi.org/10.4240/wjgs.v15.i3.323